{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.42","upperLimit":"8.18","value":"5.82"},{"groupId":"OG001","lowerLimit":"2.86","upperLimit":"6.11","value":"4.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause per RECIST version 1.1.","dispersionType":"99% Confidence Interval","groups":[{"description":"Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.","id":"OG000","title":"Single-Agent Cabozantinib"},{"description":"Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.","id":"OG001","title":"Control Arm: Sorafenib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants randomized to the single agent cabozantinib arm and control (sorafenib) arm.","reportingStatus":"POSTED","timeFrame":"From the date of first participant randomization up to 28 months","title":"PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population","type":"SECONDARY","unitOfMeasure":"months"}